Spero Therapeutics (SPRO) Equity Ratio (2016 - 2025)
Spero Therapeutics (SPRO) has disclosed Equity Ratio for 10 consecutive years, with 0.49 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Ratio rose 0.91% year-over-year to 0.49, compared with a TTM value of 0.49 through Sep 2025, up 0.91%, and an annual FY2024 reading of 0.42, down 28.81% over the prior year.
- Equity Ratio was 0.49 for Q3 2025 at Spero Therapeutics, down from 0.53 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.83 in Q1 2021 and bottomed at 0.42 in Q4 2024.
- Average Equity Ratio over 5 years is 0.56, with a median of 0.54 recorded in 2024.
- The sharpest move saw Equity Ratio plummeted 48.3% in 2022, then surged 34.48% in 2023.
- Year by year, Equity Ratio stood at 0.52 in 2021, then grew by 17.89% to 0.61 in 2022, then decreased by 3.68% to 0.59 in 2023, then decreased by 28.81% to 0.42 in 2024, then grew by 17.22% to 0.49 in 2025.
- Business Quant data shows Equity Ratio for SPRO at 0.49 in Q3 2025, 0.53 in Q2 2025, and 0.44 in Q1 2025.